Institute of Molecular Bioimaging and Physiology, National Research Council (IBFM-CNR), Cefalù, Italy.
Ri.MED Foundation, Palermo, Italy.
BMC Bioinformatics. 2020 Sep 16;21(Suppl 8):325. doi: 10.1186/s12859-020-03647-7.
Positron Emission Tomography (PET) is increasingly utilized in radiomics studies for treatment evaluation purposes. Nevertheless, lesion volume identification in PET images is a critical and still challenging step in the process of radiomics, due to the low spatial resolution and high noise level of PET images. Currently, the biological target volume (BTV) is manually contoured by nuclear physicians, with a time expensive and operator-dependent procedure. This study aims to obtain BTVs from cerebral metastases in patients who underwent L-[C]methionine (11C-MET) PET, using a fully automatic procedure and to use these BTVs to extract radiomics features to stratify between patients who respond to treatment or not. For these purposes, 31 brain metastases, for predictive evaluation, and 25 ones, for follow-up evaluation after treatment, were delineated using the proposed method. Successively, 11C-MET PET studies and related volumetric segmentations were used to extract 108 features to investigate the potential application of radiomics analysis in patients with brain metastases. A novel statistical system has been implemented for feature reduction and selection, while discriminant analysis was used as a method for feature classification.
For predictive evaluation, 3 features (asphericity, low-intensity run emphasis, and complexity) were able to discriminate between responder and non-responder patients, after feature reduction and selection. Best performance in patient discrimination was obtained using the combination of the three selected features (sensitivity 81.23%, specificity 73.97%, and accuracy 78.27%) compared to the use of all features. Secondly, for follow-up evaluation, 8 features (SUV, SUL, SUV, SUL prod-surface-area, SUV prod-sphericity, surface mean SUV 3, SUL prod-sphericity, and second angular moment) were selected with optimal performance in discriminant analysis classification (sensitivity 86.28%, specificity 87.75%, and accuracy 86.57%) outperforming the use of all features.
The proposed system is able i) to extract 108 features for each automatically segmented lesion and ii) to select a sub-panel of 11C-MET PET features (3 and 8 in the case of predictive and follow-up evaluation), with valuable association with patient outcome. We believe that our model can be useful to improve treatment response and prognosis evaluation, potentially allowing the personalization of cancer treatment plans.
正电子发射断层扫描(PET)越来越多地用于治疗评估目的的放射组学研究。然而,由于 PET 图像的空间分辨率低且噪声水平高,因此在放射组学过程中,病变体积的识别是一个关键且仍然具有挑战性的步骤。目前,核医学医师通过手动勾画生物靶区(BTV),这是一个耗时且依赖于操作者的过程。本研究旨在使用全自动程序从接受 L-[C]蛋氨酸(11C-MET)PET 的脑转移患者中获得 BTV,并使用这些 BTV 提取放射组学特征,以对治疗有反应和无反应的患者进行分层。为此,使用所提出的方法对 31 个脑转移瘤进行预测性评估,对 25 个脑转移瘤进行治疗后随访评估。随后,使用 11C-MET PET 研究和相关的体积分割来提取 108 个特征,以研究放射组学分析在脑转移患者中的潜在应用。实施了一种新的统计系统进行特征降维和选择,同时使用判别分析作为特征分类的方法。
在预测性评估中,经过特征降维和选择后,3 个特征(各向异性度、低强度运行强调和复杂度)能够区分应答者和无应答者患者。使用三个选定特征(灵敏度 81.23%、特异性 73.97%和准确性 78.27%)的组合与使用所有特征相比,患者的区分性能最佳。其次,在随访评估中,使用判别分析分类选择了 8 个特征(SUV、SUL、SUV、SUL prod-surface-area、SUV prod-sphericity、surface mean SUV 3、SUL prod-sphericity 和第二角度矩),性能最佳(灵敏度 86.28%、特异性 87.75%和准确性 86.57%)优于使用所有特征。
所提出的系统能够 i)为每个自动分割的病变提取 108 个特征,ii)选择 11C-MET PET 特征的子面板(预测和随访评估的 3 和 8 个),与患者结果有有价值的关联。我们相信我们的模型可以帮助改善治疗反应和预后评估,有可能使癌症治疗计划个性化。